Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Joanne Towers

Physician Assistant Fairfax, VA Physician Assistant

NPI 1932681376 CMS profile 10504334

3025 Hamaker Court Suite 300, Fairfax, VA 22031

Open in the dashboard

General payments

$23,495

697 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joanne Towers of Fairfax, VA is reported in the CMS Open Payments database as having received $23,495 across 697 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,543 205
2024 General $5,264 162
2023 General $4,311 127
2022 General $3,668 110
2021 General $2,709 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joanne Towers
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Joanne Towers were reported at $7,543. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Joanne Towers Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,709 $132 $37–$438 $132
2022 $3,668 $155 $48–$522 $149
2023 $4,311 $167 $52–$557 $160
2024 $5,264 $178 $55–$600 $164
2025 $7,543 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,922 86 payments
  2. Incyte Corporation $2,135 71 payments
  3. Janssen Biotech, Inc. $2,084 67 payments
  4. UCB, Inc. $2,013 34 payments
  5. E.R. Squibb & Sons, L.L.C. $1,704 53 payments
  6. Lilly USA, LLC $1,421 34 payments
  7. Regeneron Healthcare Solutions, Inc. $1,260 37 payments
  8. Galderma Laboratories, L.P. $1,260 39 payments
  9. LEO Pharma Inc. $1,108 41 payments
  10. Ortho Dermatologics, a division of Bausch Health US, LLC $1,078 55 payments
  11. Other $6,510 180 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $21,814 687 payments
  2. Consulting Fee $1,140 1 payment
  3. Education $538 8 payments
  4. Travel and Lodging $3 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $2,351 53 payments
  2. OPZELURA $1,927 69 payments
  3. SKYRIZI $1,808 49 payments
  4. Bimzelx $1,731 19 payments
  5. SOTYKTU $1,677 52 payments
  6. DUPIXENT Immunology $991 21 payments
  7. ADBRY $845 32 payments
  8. DUPIXENT Inflammation And Immunology $767 22 payments
  9. TALTZ $697 27 payments
  10. JUBLIA $669 47 payments
  11. Other $11,869 483 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

579

Median for Physician Assistant: 241

Drug cost

$247,606

Median for Physician Assistant: $4,110

Branded share of claims

14.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sotyktu Deucravacitinib Brand 17 $112,863
Dupixent Pen Dupilumab Brand 13 $88,215
Jublia Efinaconazole Brand 11 $11,583
Zoryve Roflumilast Brand 12 $10,190
Winlevi Clascoterone Brand 12 $7,045
Clobetasol Propionate Generic 118 $6,595
Tacrolimus Generic 18 $1,377
Fluorouracil Generic 21 $1,315
Econazole Nitrate Generic 16 $1,114
Tretinoin Generic 16 $1,067

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$112,662

Of which drugs: $63

Medicare patients

574

Average age 75

Services billed

2,732

307 women, 267 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 41%
Ischemic heart disease 25%
Chronic kidney disease 18%
Diabetes 17%
Atrial fibrillation 16%
Osteoporosis 16%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 80 $54

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
$786 17 —
OPZELURA
$592 — —
DUPIXENT
$471 13 —
SKYRIZI
$423 — —
TREMFYA
$364 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

697 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record